LAUSR

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2019): Non-Sponsored Symposia Abstracts # International Osteoporosis Foundation and National Osteoporosis Foundation 2019 NS1 ROUTINELY COLLECTED DATA FOR THE STUDY OF THE EPIDEMIOLOGY OF FRACTURES, AND FOR CHARACTERISING IMMINENT FRACTURE RISK B. Abrahamsen Holbæk Hospital, Holbæk, Denmark; University of Southern Denmark, Odense, Denmark Prof Bo Abrahamsen will discuss the use of real world (routinely collected) data for the study of the epidemiology of metabolic bone disease, including osteoporosis, fracture/s, and osteonecrosis of the jaw. He will start by introducing the audience briefly to a number of different data sources available around Europe, including Scandinavian registries and primary care and hospital electronic medical records. Prof Abrahamsen will then cover his previous work on the epidemiology of fracture/s in Denmark, including both major osteoporotic and other fractures. He will also discuss previous work on the descriptive epidemiology of jaw osteonecrosis and subtrochanteric fracture/s, and their association with the use of oral bisphosphonates in actual practice conditions and patients. NS2 REAL WORLD DATA FOR ASSESSING THE USE, RISKS, AND BENEFITS OF ANTI-OSTEOPOROSIS THERAPIES IN ACTUAL PRACTICE CONDITIONS D. Prieto-Alhambra University of Oxford, Oxford, United Kingdom Prof Prieto-Alhambra will start with a brief presentation on the ‘pros and cons’ of the use of routinely collected data in postmarketing surveillance, with a focus on drug utilisation and safety studies in Europe. Daniel will then discuss the use of routinely collected data from multiple data sources in Europe for the study of the conditions of use and prevalence/incidence of prescription/s of anti-osteoporosis treatments in different countries/regions, and the implications of such information for regulators and decision makers. He will then discuss briefly methodological aspects for consideration when performing any analyses of association/s between the use of drugs and their potential side effects. Prof Prieto-Alhambra will finish this presentation with a brief introduction to the concept of federated distributed data networks to enable multinational collaboration in the field. NS3 HEALTHECONOMICSUSINGREALWORLDDATA: AN INTRODUCTION R. Pinedo-Villanueva University of Oxford, Oxford, United Kingdom Dr Pinedo-Villanueva will start with a brief introduction to the concepts of costs as recorded in routinely collected data. He will discuss his experience with the use of such data for the research of the costs and benefits of a number of musculoskeletal treatments and conditions. He will summarise the findings of his work on the health economics of hip and knee arthroplasty using a number of different real world data sources. He will then summarise his recent work on the costs of sarcopenia, to finish with a synopsis of his recent and current work on characterising the costs of musculoskeletal rare disease/s. NS4 REAL WORLD DATA FOR THE STUDY OF ORTHOPAEDICS AND HIP FRACTURE CARE A. Pedersen Southern Denmark University, Odense, Denmark Prof Pedersen will cover the use of real world data for the study of orthopaedics, with a focus on hip fracture epidemiology and care. Osteoporosis International (2019) 30 (Suppl 2):S219–S251 https://doi.org/10.1007/s00198-019-04986-9